查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985735

心肺體外迴圈裝置市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Cardiopulmonary Bypass Equipment Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心肺體外迴圈設備市場價值將達到 3.2974 億美元，到 2026 年將成長至 3.4263 億美元，到 2032 年將達到 4.561 億美元，複合年成長率為 4.74%。

主要市場統計數據
基準年 2025 3.2974億美元
預計年份：2026年 3.4263億美元
預測年份 2032 4.561億美元
複合年成長率 (%) 4.74%

對心肺體外迴圈設備在臨床實踐中的定位、採購重點、技術進步和醫療保健決策框架進行策略性概述。

本執行摘要首先將心肺體外迴圈裝置置於心臟外科手術的廣泛領域中進行分析，指出裝置的可靠性、生物相容性和手術效率直接影響臨床結果。本文涵蓋的裝置包括用於心血管手術期間體外循環的裝置和一次性用品，這些裝置和用品與臨床通訊協定、灌注師操作規範以及醫療機構的採購重點密切相關。隨著醫院和專科心臟中心的團隊重新思考工作流程以最佳化治療效果並控制成本，了解裝置功能、使用者工程和病人安全之間的相互作用至關重要。

膜設計、泵浦機制、塗層和臨床工作流程的進步如何全面重塑採購、臨床實踐和設備開發路徑。

心肺體外迴圈裝置領域正經歷一場變革，其驅動力來自臨床需求、技術創新以及對安全性和效率日益成長的期望。膜式氧合器材料的進步，包括中空纖維形狀和板式設計的改進，在提升氣體交換性能的同時，也減少了血液損傷。同時，泵浦技術也在不斷發展，更耐用的離心機構和更精確的滾壓幫浦控制，正在改變灌注師的工作流程和設備配置。

關稅引發的供應鏈變化對零件採購、到貨成本趨勢、供應商多元化和採購彈性策略的連鎖反應。

美國近期推出的政策措施為整個心肺體外迴圈設備供應鏈帶來了新的挑戰，影響成本結構、庫存策略和採購決策。依賴跨境生產零件（例如用於氧合器膜的特殊聚合物、用於插管和泵殼的精密金屬零件或藥用級塗層）的製造商將受到關稅的更大影響，關稅可能導致進口成本增加。因此，許多供應商正在調整供應鏈結構，以在維持服務水準的同時維持利潤率。

詳細的細分分析揭示了產品系列、臨床應用、最終用戶環境和技術選擇如何相互作用，從而塑造採購和部署模式。

基於細分市場的詳細分析為產品開發、臨床應用和銷售策略提供了切實可行的見解。按產品類型分類，市場包括附件、插管、過濾器、氧合器和幫浦。附件包括儲液器和導管，而插管則分為動脈插管和靜脈插管，設計用於滿足不同的解剖結構和流量需求。過濾器包括血液濃縮器和白血球去除過濾器，它們在體液管理和發炎調節中發揮不同的作用。氧合器則分為膜式和微孔式兩種結構。在膜式氧合器中，板式和中空纖維式結構在表面積、預充能力和氣體傳輸效率方面各有優劣。泵浦則分為離心式和滾壓式兩種技術，每種技術在溶血風險、維護特性以及與輔助監測系統的兼容性方面都存在差異。

美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、採購慣例和臨床能力如何影響商業化和服務策略？

區域趨勢對美洲、歐洲、中東和非洲以及亞太市場的臨床實踐、監管路徑和商業策略都有顯著影響。在美洲，大規模醫院系統和學術醫療中心主導醫療採購，它們要求設備具備強力的臨床療效證據、完善的服務網路，並能與電子健康記錄和灌注監測平台無縫整合。該地區的支付模式和醫院採購週期旨在確保設備的持久性能，並與供應商建立長期夥伴關係。

成熟製造商、專業創新者和以服務為導向的供應商之間的競爭行為和策略應對措施決定了市場領導地位和商業性差異化。

心肺體外迴圈設備領域的競爭動態呈現出多元化的特點，既有成熟的外科醫療設備製造商，也有專業的體外循環系統供應商，還有專注於利基創新技術的參與企業。成熟的製造商擁有涵蓋一次性產品、大型設備和綜合服務合約的廣泛產品組合，導致轉換成本高且產品生命週期較長。同時，中小企業和Start-Ups則透過新型薄膜材料、低預充氧器設計以及先進的泵浦控制演算法等創新技術脫穎而出，吸引專科醫療中心和研究型醫院的目光。

為製造商和供應商提供可操作的策略重點，以最佳化其產品組合、保障供應鏈、產生臨床證據、擴大服務範圍並實現永續性目標。

產業領導企業可以採取一系列切實可行的優先事項，在應對營運限制的同時，鞏固市場地位並支持臨床療效。首先，他們可以優先精簡產品組合，使產品複雜性與核心終端使用者需求相匹配，減少缺乏臨床證據區分的SKU，並將創新重點放在新生兒、兒童或成人細分市場需要獨特解決方案的領域。其次，他們可以透過關鍵零件供應商多元化和協商合約保障措施來降低關稅和物流波動風險，從而投資於供應鏈韌性。

為了檢驗營運洞察並為戰略重點的製定提供資訊，我們採用了一種嚴格的混合方法，結合了對臨床醫生的訪談、監管審查和技術文獻。

本分析的研究基礎是將對臨床醫生、灌注技師、採購經理和行業高管的定性訪談與監管文件、技術白皮書和同行評審的臨床文獻進行二次檢驗相結合。主要研究聚焦於代表性的醫院、心臟中心和門診手術中心，旨在了解醫療設備的實際表現、臨床醫師的偏好、服務期望和採購限制。訪談樣本刻意納入了同時服務成人和兒童患者的灌注技師，以全面了解醫療設備在所有臨床領域的表現。

整合策略挑戰，展示技術、供應鏈韌性和有針對性的商業性方法如何整合，以支援臨床部署和營運穩定性。

總之，心肺體外迴圈設備市場正處於一個轉折點，技術進步、政策壓力和不斷變化的臨床需求相互交織，重塑採購和臨床實踐。氧合器設計、幫浦機制和表面塗層的進步帶來了切實的臨床效益，但其成功應用需要與服務基礎設施、臨床醫生培訓和籌資策略進行精心協調。關稅導致的供應鏈調整凸顯了採購多元化和提高零件來源透明度的必要性，而不同地區在法規和臨床能力方面的差異則要求採取因地制宜的市場策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心肺體外迴圈裝置市場：依產品類型分類

  • 配件
    • 水庫
    • 管子
  • 套管
    • 動脈
    • 靜脈
  • 篩選
    • 血液濃縮器
    • 白血球過濾器
  • 氧合器
    • 電影
      • 平板型
      • 中空纖維
    • 微孔
  • 泵浦
    • 離心式
    • 滾筒

第9章：心肺體外迴圈裝置市場：依技術分類

  • 塗層類型
    • 肝素塗層
    • 未塗層
  • 操作模式
    • 非脈衝型
    • 脈衝型

第10章：心肺體外迴圈裝置市場：依應用領域分類

  • 成人版
  • 新生
  • 兒童

第11章心肺體外迴圈裝置市場：依最終用戶分類

  • 門診手術中心
  • 心臟外科中心
  • 醫院

第12章心肺體外迴圈裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章心肺體外迴圈裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章心肺體外迴圈裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國心肺體外迴圈機市場

第16章：中國心肺體外迴圈機市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Beijing ZKSK Technology Co., Ltd.
  • Braile Biomedica
  • Brightwake Limited
  • Chalice Medical Ltd.
  • Fresenius Kabi
  • Getinge AB
  • Global Blood Resources, LLC
  • Johnson & Johnson Services, Inc.
  • LivaNova PLC
  • MAQUET Holding BV & Co. KG.
  • MC3 Cardiopulmonary
  • Medtronic Plc
  • MicroPort Scientific Corporation
  • Nipro Corporation
  • Owgels Group
  • Precision Medical, Inc.
  • ProCell Surgical Inc.
  • Senko Medical Instrument Manufacturing Co.,Ltd.
  • Sorin Group
  • Stryker Corporation
  • Technowood Corporation
  • Teleflex Incorporated
  • Terumo Group
  • Xenios AG
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-757B1C9CB0B8

The Cardiopulmonary Bypass Equipment Market was valued at USD 329.74 million in 2025 and is projected to grow to USD 342.63 million in 2026, with a CAGR of 4.74%, reaching USD 456.10 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 329.74 million
Estimated Year [2026] USD 342.63 million
Forecast Year [2032] USD 456.10 million
CAGR (%) 4.74%

A strategic overview placing cardiopulmonary bypass equipment within clinical practice, procurement priorities, technological progress and institutional decision frameworks

This executive summary opens by situating cardiopulmonary bypass equipment within the broader continuum of cardiac surgical care, where device reliability, biocompatibility, and procedural efficiency directly influence clinical outcomes. The equipment set covered spans devices and disposables that enable extracorporeal circulation during cardiac procedures, and it interacts closely with clinical protocols, perfusionist practice, and institutional procurement priorities. As teams across hospitals and specialized cardiac centers recalibrate workflows to optimize outcomes and contain costs, understanding the interplay among device functionality, user ergonomics, and patient safety has become essential.

Clinical adoption is shaped by both micro-level operational needs-such as ease of setup, priming volumes, and compatibility with monitoring systems-and macro-level forces including regulatory scrutiny and supply chain resilience. Technological advances in oxygenator membrane design and pump mechanics have reduced complication rates and simplified perioperative management, yet they have also introduced new decision criteria around training, disposables inventory, and vendor consolidation. Consequently, hospital administrators and perfusion leaders must synthesize clinical performance data with procurement considerations to select systems that align with institutional case mix and long-term capital plans.

The introduction concludes by framing the remainder of this summary as a practical synthesis: it highlights structural shifts, policy influences, segmentation nuances, regional dynamics, competitor behaviors, and targeted recommendations that together form a foundation for immediate strategic action by manufacturers, providers, and investors.

How advancements in membrane design, pump mechanics, coatings, and clinical workflows are collectively reshaping procurement, clinical practice, and device development pathways

The landscape for cardiopulmonary bypass equipment is undergoing transformative shifts driven by converging clinical priorities, engineering innovation, and heightened expectations for safety and efficiency. Advances in membrane oxygenator materials, including the refinement of hollow fiber geometries and flat plate designs, are delivering improved gas exchange characteristics while reducing blood trauma. At the same time, pump technologies have evolved with more durable centrifugal mechanics and more precise roller pump controls, altering perfusionist workflows and inventory configurations.

Beyond device evolution, systemic change is evident in the emphasis on coatings and surface treatments to mitigate thrombogenicity. Heparin-coated circuits and alternative biocompatible coatings are increasingly considered where anticoagulation management is complex, creating a differentiated value proposition between coated and non-coated systems. Mode of operation considerations-non-pulsatile versus pulsatile flow-are also influencing hospital purchasing decisions as clinicians weigh hemodynamic fidelity against device complexity and cost of disposables.

Operationally, there is a clear shift toward integrated circuit sets and single-use platforms that promise faster turnover and reduced contamination risk, but these benefits must be balanced against waste management and sustainability goals. In parallel, adoption patterns in neonatal and pediatric subsegments demand specialized cannulae and oxygenators sized for lower flow volumes and different priming strategies, prompting suppliers to refine product families to match patient demographics. Taken together, these shifts are driving a more nuanced procurement dialogue that places patient safety, clinician experience, and lifecycle total cost at the center of equipment selection.

The ripple effects of tariff-induced supply chain shifts on component sourcing, landed cost dynamics, supplier diversification, and procurement resilience strategies

Recent tariff developments originating from United States policy actions have introduced novel considerations across supply chains for cardiopulmonary bypass equipment, affecting cost structures, inventory strategies, and sourcing decisions. Manufacturers that rely on cross-border production of components such as specialized polymers for oxygenator membranes, precision metalwork for cannulae and pump housings, or pharmaceutical-grade coatings face increased exposure to duties that can alter landed costs. As a result, many suppliers are reassessing their supply chain architectures to preserve margin while maintaining service levels.

Procurement teams at hospitals and cardiac centers are responding by expanding supplier qualification frameworks and prioritizing dual-source strategies that reduce single-vendor risk. Where tariffs increase the relative cost of imported components, some original equipment manufacturers are accelerating localization efforts or renegotiating contracts to include tariff pass-through clauses. These measures underscore a shift from purely price-driven sourcing to a more resilient procurement posture that values lead-time assurance and component traceability.

Regulatory and contracting effects are also apparent: purchasing groups and health systems increasingly require transparency on the origin of components and warranty implications when manufacturing locations change. Clinicians and perfusion teams may face transition periods when product specifications shift due to component substitutions intended to mitigate tariff impacts. Therefore, institutional stakeholders should plan for validation cycles, training refreshers, and inventory buffers to avoid disruptions to surgical schedules while suppliers pursue longer-term realignment of manufacturing footprints.

Deep segmentation analysis revealing how product families, clinical applications, end-user environments, and technology choices interact to shape procurement and adoption patterns

Analyzing the market through detailed segmentation reveals actionable implications for product development, clinical adoption, and sales strategies. When viewed by product type, the landscape encompasses Accessories, Cannulae, Filters, Oxygenators, and Pumps; Accessories include Reservoirs and Tubing, and Cannulae comprise Arterial and Venous variants designed for distinct anatomical and flow requirements. Filters span Hemoconcentrators and Leukocyte Filters, which play differentiated roles in fluid management and inflammatory modulation, while Oxygenators are available in Membrane and Microporous constructs. Within membrane oxygenators, Flat Plate and Hollow Fiber architectures present tradeoffs in surface area, priming volume, and gas transfer efficiency. Pumps bifurcate into Centrifugal and Roller technologies, each with implications for hemolysis risk, maintenance profiles, and compatibility with ancillary monitoring systems.

Application segmentation differentiates adult, neonatal, and pediatric use cases, a distinction that materially affects device sizing, priming strategies, and circuit design. Neonatal and pediatric applications demand low-volume, high-precision solutions with specialized cannulae and oxygenator characteristics, whereas adult applications often emphasize durability and throughput. End user segmentation across Ambulatory Surgery Centers, Cardiac Surgery Centers, and Hospitals influences purchasing cycles and service expectations; ambulatory centers prioritize streamlined disposables and rapid turnover, cardiac surgery centers often demand high-performance customizable systems, and hospitals balance versatility with cost containment across broader case mixes.

Technology segmentation highlights coating type and mode of operation as pivotal decision variables. Coating options include Heparin Coated and Non Coated surfaces, with coated circuits offering a clinical rationale in patients at higher thrombotic risk or where lower systemic anticoagulation is desirable. Mode of operation divides into Non Pulsatile and Pulsatile systems, a choice that informs both physiological support characteristics and system complexity. Collectively, these segmentation lenses create a matrix that manufacturers and providers can use to align product portfolios with clinical needs, procurement constraints, and user preferences.

How regional regulatory diversity, procurement practices and clinical capacity across the Americas, Europe Middle East & Africa, and Asia-Pacific shape commercialization and service strategies

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, institutional purchasing is characterized by large hospital systems and academic centers that demand robust evidence of clinical efficacy, strong service networks, and integration with electronic health records and perfusion monitoring platforms. Payment models and hospital procurement cycles in this region incentivize durable equipment performance and long-term vendor partnerships.

In Europe, Middle East & Africa, regulatory diversity and reimbursement variability require manufacturers to pursue harmonized clinical data that can support multiple approval pathways and value dossiers. Procurement in this region often emphasizes cost-effectiveness and lifecycle support across disparate healthcare delivery settings, from advanced cardiac centers to under-resourced facilities. The Asia-Pacific region is marked by rapid expansion of cardiac surgical capacity, investment in local manufacturing, and a growing emphasis on point-of-care optimization. Demand in Asia-Pacific is driven by both rising procedure volumes and evolving expectations for device affordability and local service capabilities.

Across regions, differences in clinical protocols, staff training paradigms, and waste management regulations create practical implications for device design and aftersales service. Manufacturers should calibrate market entry strategies to address regional reimbursement nuances, local clinical evidence generation, and the logistical requirements of providing responsive technical support. Strategic partnerships with regional distributors and investments in education for perfusion teams and surgical staff will be critical to unlock adoption across these heterogeneous markets.

Competitive behaviors and strategic responses among established manufacturers, focused innovators, and service-oriented providers that define market leadership and commercial differentiation

Competitive dynamics in the cardiopulmonary bypass equipment space are defined by a mix of established surgical device manufacturers, specialized perfusion system providers, and emerging technology entrants focused on niche innovations. Incumbent manufacturers leverage broad portfolios that span disposables, capital equipment, and integrated service contracts, creating high switching costs and extended product lifecycles. Meanwhile, smaller firms and start-ups push differentiation through novel membrane materials, low-priming-volume oxygenator designs, and advanced pump control algorithms that appeal to specialty centers and research hospitals.

Market participants are increasingly pursuing partnerships with clinical centers to co-develop next-generation systems, validate novel coatings, and run post-market surveillance studies that demonstrate real-world benefits. Supply chain collaborations, contract manufacturing models, and selective vertical integration are common strategic responses to procurement pressures and tariff exposure. Additionally, companies are investing in digital capabilities around device telemetry and predictive maintenance to enhance uptime and demonstrate value beyond the initial purchase.

For sales and commercial teams, the imperative is to articulate clinical value clearly to perfusionists, cardiac surgeons, and purchasing committees. This includes providing evidence of reduced complication rates, simplified workflows, and total cost of operation over relevant lifecycle horizons without relying solely on price as the differentiator. Firms that can combine robust clinical support, rapid technical service, and flexible contracting options will gain traction among hospital systems and specialized cardiac centers.

Practical strategic priorities for manufacturers and providers to optimize portfolios, secure supply chains, generate clinical evidence, expand service offerings, and address sustainability objectives

Industry leaders can pursue a set of actionable priorities to strengthen market positions and support clinical outcomes while addressing operational constraints. First, prioritize portfolio rationalization that aligns product complexity with core end-user needs, reducing SKUs where clinical evidence does not support differentiation and concentrating innovation where neonatal, pediatric, or adult subsegments demand unique solutions. Second, invest in supply chain resilience by diversifying suppliers of critical components and negotiating contractual protections that mitigate tariff and logistics volatility.

Third, deepen clinical partnerships that support evidence generation, including registries and collaborative studies that validate the benefits of membrane types, coatings, and pulsatile modality in relevant patient cohorts. Fourth, expand aftersales service models to include remote diagnostics, predictive maintenance, and training programs that reduce downtime and improve adoption confidence among perfusion staff. Fifth, tailor go-to-market approaches by region: emphasize regulatory alignment and value dossiers in Europe, performance and service in the Americas, and affordability plus local support in Asia-Pacific.

Finally, integrate sustainability and waste reduction into product and packaging design to meet institutional ESG goals and evolving procurement criteria. Executed together, these actions will help manufacturers and providers deliver measurable clinical benefits, strengthen commercial differentiation, and reduce operational risk in a shifting policy and supply chain environment.

A rigorous mixed-methods research approach combining clinician interviews, regulatory review, and technical literature to validate operational insights andinform strategic priorities

The research underlying this analysis synthesizes primary qualitative interviews with clinicians, perfusionists, procurement leaders, and industry executives alongside secondary validation from regulatory filings, technical white papers, and peer-reviewed clinical literature. Primary engagement focused on understanding real-world device performance, clinician preferences, service expectations, and procurement constraints across a representative set of hospitals, cardiac centers, and ambulatory surgical facilities. Interview sampling deliberately included perfusionists working with both adult and pediatric populations to capture device performance across the clinical spectrum.

Secondary sources provided technical context on membrane materials, pump mechanics, and coating science and were used to corroborate themes that emerged in interviews. The methodology applied a cross-sectional thematic analysis to identify recurring operational pain points, technology priorities, and procurement behaviors, and these themes were mapped against product segmentation and regional dynamics to derive actionable recommendations. To ensure accuracy and relevance, the analysis included iterative validation with subject matter experts and a review of recent regulatory communications that affect device design and labeling.

This combined approach produced a pragmatic synthesis designed to inform commercial strategy, clinical adoption pathways, and procurement decisions without relying on speculative market projections. The result is a robust evidence base that stakeholders can use to prioritize investments, modify go-to-market strategies, and align product roadmaps with clinical and operational realities.

Synthesis of strategic imperatives showing how technology, supply chain resilience and targeted commercial approaches converge to support clinical adoption and operational stability

In conclusion, the cardiopulmonary bypass equipment environment is at an inflection point where technology improvements, policy pressures, and evolving clinical expectations converge to reshape procurement and clinical practice. Advances in oxygenator design, pump mechanics, and surface coatings are delivering tangible clinical benefits, yet their successful adoption depends on careful alignment with service capabilities, clinician training, and procurement strategies. Tariff-induced supply chain adjustments have underscored the need for diversified sourcing and greater transparency around component provenance, while regional differences in regulation and clinical capacity call for tailored market approaches.

Manufacturers that emphasize resilient supply chains, focused product portfolios, robust clinical partnerships, and comprehensive aftersales support will be better positioned to meet the complex needs of hospitals, cardiac centers, and ambulatory facilities. Similarly, providers that integrate device selection with staff training, inventory management, and sustainability considerations will maximize clinical outcomes and operational efficiencies. The strategic actions outlined in this summary offer a roadmap for stakeholders seeking to balance innovation adoption with pragmatic operational risk management in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiopulmonary Bypass Equipment Market, by Product Type

  • 8.1. Accessories
    • 8.1.1. Reservoirs
    • 8.1.2. Tubing
  • 8.2. Cannulae
    • 8.2.1. Arterial
    • 8.2.2. Venous
  • 8.3. Filters
    • 8.3.1. Hemoconcentrators
    • 8.3.2. Leukocyte Filters
  • 8.4. Oxygenators
    • 8.4.1. Membrane
      • 8.4.1.1. Flat Plate
      • 8.4.1.2. Hollow Fiber
    • 8.4.2. Microporous
  • 8.5. Pumps
    • 8.5.1. Centrifugal
    • 8.5.2. Roller

9. Cardiopulmonary Bypass Equipment Market, by Technology

  • 9.1. Coating Type
    • 9.1.1. Heparin Coated
    • 9.1.2. Non Coated
  • 9.2. Mode Of Operation
    • 9.2.1. Non Pulsatile
    • 9.2.2. Pulsatile

10. Cardiopulmonary Bypass Equipment Market, by Application

  • 10.1. Adult
  • 10.2. Neonatal
  • 10.3. Pediatric

11. Cardiopulmonary Bypass Equipment Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Cardiac Surgery Centers
  • 11.3. Hospitals

12. Cardiopulmonary Bypass Equipment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiopulmonary Bypass Equipment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiopulmonary Bypass Equipment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cardiopulmonary Bypass Equipment Market

16. China Cardiopulmonary Bypass Equipment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Beijing ZKSK Technology Co., Ltd.
  • 17.8. Braile Biomedica
  • 17.9. Brightwake Limited
  • 17.10. Chalice Medical Ltd.
  • 17.11. Fresenius Kabi
  • 17.12. Getinge AB
  • 17.13. Global Blood Resources, LLC
  • 17.14. Johnson & Johnson Services, Inc.
  • 17.15. LivaNova PLC
  • 17.16. MAQUET Holding B.V. & Co. KG.
  • 17.17. MC3 Cardiopulmonary
  • 17.18. Medtronic Plc
  • 17.19. MicroPort Scientific Corporation
  • 17.20. Nipro Corporation
  • 17.21. Owgels Group
  • 17.22. Precision Medical, Inc.
  • 17.23. ProCell Surgical Inc.
  • 17.24. Senko Medical Instrument Manufacturing Co.,Ltd.
  • 17.25. Sorin Group
  • 17.26. Stryker Corporation
  • 17.27. Technowood Corporation
  • 17.28. Teleflex Incorporated
  • 17.29. Terumo Group
  • 17.30. Xenios AG
  • 17.31. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY RESERVOIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TUBING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEMOCONCENTRATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY LEUKOCYTE FILTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FLAT PLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOLLOW FIBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MICROPOROUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ROLLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HEPARIN COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NON PULSATILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PULSATILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CARDIAC SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 223. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 262. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 270. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 275. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 283. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. NATO CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY OXYGENATORS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MEMBRANE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PUMPS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY COATING TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY ACCESSORIES, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY CANNULAE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA CARDIOPULMONARY BYPASS EQUIPMENT MARKET SIZE, BY FILTERS, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA CARDIOPULMONARY